27,558 Biogen Inc. $BIIB Shares Purchased by Capital Investment Advisors LLC

Capital Investment Advisors LLC lifted its position in shares of Biogen Inc. (NASDAQ:BIIB) by 1,347.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 29,603 shares of the biotechnology company’s stock after buying an additional 27,558 shares during the quarter. Capital Investment Advisors LLC’s holdings in Biogen were worth $6,687,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of BIIB. BlackRock Inc. purchased a new position in shares of Biogen during the 2nd quarter worth $3,453,878,000. Primecap Management Co. CA purchased a new stake in Biogen in the second quarter valued at approximately $3,274,304,000. Wellington Management Group LLP grew its holdings in Biogen by 5.3% in the second quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock valued at $673,560,000 after purchasing an additional 155,828 shares during the period. Amundi raised its stake in Biogen by 91.8% during the second quarter. Amundi now owns 1,516,831 shares of the biotechnology company’s stock worth $327,727,000 after purchasing an additional 726,004 shares during the period. Finally, Legal & General Group Plc purchased a new stake in shares of Biogen during the 2nd quarter valued at $322,640,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on BIIB shares. Royal Bank Of Canada lowered their price target on Biogen from $260.00 to $256.00 and set an “outperform” rating for the company in a research report on Thursday, October 8th. Weiss Ratings raised shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, September 24th. Needham & Company LLC raised their price target on shares of Biogen from $255.00 to $256.00 and gave the company a “buy” rating in a report on Monday, June 29th. Wedbush increased their price objective on shares of Biogen from $201.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, July 30th. Finally, Oppenheimer restated an “outperform” rating and set a $300.00 target price on shares of Biogen in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $241.89.

Biogen Stock Performance

Biogen stock opened at $250.69 on Friday. Biogen Inc. has a 12-month low of $138.00 and a 12-month high of $254.41. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26. The company has a market capitalization of $37.04 billion, a price-to-earnings ratio of 18.17, a price-to-earnings-growth ratio of 2.83 and a beta of 0.09. The firm’s fifty day moving average price is $223.60 and its 200 day moving average price is $206.04.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, topping the consensus estimate of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The business had revenue of $2.74 billion for the quarter, compared to analysts’ expectations of $2.46 billion. During the same quarter in the previous year, the firm posted $5.47 earnings per share. The company’s revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, research analysts forecast that Biogen Inc. will post 12.29 EPS for the current fiscal year.

Biogen Company Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.